Biogen Inc

BIIBNASDAQ · USD
249.59USD0.00 (+1.00%)
6310

Biogen Inc (BIIB) Wheel Strategy

BIIB wheel strategy scan found 191 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 285.2%.

Read more

Running a BIIB wheel strategy lets you generate consistent premium income on Biogen Inc while setting your own entry and exit prices on the underlying. Biogen Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own BIIB, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best BIIB wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on BIIB, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable BIIB wheel from a losing one.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the BIIB wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your BIIB wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Nov 20, 2026240.00$0.05$1.88-0.261100%86.0%285.2%1,298
Nov 20, 2026245.00$0.20$1.90-0.381100%62.2%283.1%50
Nov 20, 2026235.00$0.05$0.63-0.121100%96.9%97.1%609
Dec 11, 2026245.00$10.00$12.05-0.4422100%50.2%81.6%0
Dec 4, 2026245.00$6.00$8.20-0.4415100%51.1%81.4%0
Nov 27, 2026245.00$2.40$4.35-0.428100%52.7%81.0%11
Dec 4, 2026242.50$5.30$7.30-0.4015100%54.5%73.3%0
Dec 11, 2026240.00$7.50$9.65-0.3822100%55.9%66.7%0
Dec 18, 2026240.00$12.10$12.45-0.3929100%54.5%65.3%522
Dec 4, 2026240.00$4.50$6.35-0.3615100%58.0%64.4%0

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →